Psilocybin, Social Cognition, and AUD: Trial Endpoints Under Scrutiny

Psilocybin May Influence Social Brain Function in AUD

Recent research suggests psilocybin, a classic serotonergic psychedelic, may modulate social brain networks in individuals with Alcohol Use Disorder (AUD). While most clinical trials for psilocybin in AUD focus on endpoints such as drinking days, abstinence rates, and craving scores, new neuroimaging and behavioral data indicate that psilocybin's effects on social cognition—such as empathy, connectedness, and social reward processing—could be central to its therapeutic action. These findings are supported by functional MRI (fMRI) studies showing altered activity in the medial prefrontal cortex and temporoparietal junction, regions implicated in social cognition, following psilocybin administration (see NCT04620759 for ongoing work). This insight challenges the field to consider whether current outcome measures fully reflect the drug's impact in real-world recovery.

Current Trial Endpoints May Miss Key Neuropsychiatric Changes

Standard endpoints in psilocybin-AUD trials, such as percent heavy drinking days or biochemical markers, may not capture improvements in social functioning or interpersonal relationships. These domains are often critical for sustained recovery, as social isolation and impaired social cognition are both risk factors and consequences of AUD. Failure to measure these changes risks underestimating the clinical benefit of psilocybin, potentially leading to negative or equivocal trial results despite meaningful improvements in patient quality of life. This disconnect is not merely academic: regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) rely on prespecified endpoints to evaluate efficacy, so the choice of outcome measures can directly affect approval prospects and label indications.

Implications for Clinical Trial Design and Policy

Researchers and sponsors are now faced with a methodological challenge: should future trials incorporate validated social cognition scales, ecological momentary assessments, or digital phenotyping to capture changes in social brain function? There is precedent for expanding endpoints—recent FDA guidance on psychiatric drug development encourages patient-centered outcomes and real-world functioning measures (FDA Guidance, 2023). However, integrating these endpoints requires rigorous validation, clear statistical analysis plans, and regulatory engagement. A non-obvious implication is that sponsors who proactively include social cognition endpoints may gain a competitive edge in demonstrating differentiated value to payers and health technology assessment bodies, not just regulators.

Risks, Unknowns, and Failure Modes

There is a risk that expanding endpoints could introduce statistical noise or complicate interpretation if measures are not robustly validated for the AUD population. Additionally, the causal relationship between changes in social cognition and drinking outcomes remains unclear—improvements in social brain function may not always translate to reduced alcohol use. Another failure mode is the potential for regulatory pushback if novel endpoints are perceived as exploratory or insufficiently linked to clinical benefit. Finally, there is the practical challenge of implementing complex neuroimaging or digital assessments in large, multisite trials, which may increase costs and operational burden.

Looking Ahead: Toward More Nuanced Evidence Standards

The evolving understanding of psilocybin's effects on the social brain in AUD highlights the need for more nuanced and multidimensional evidence standards in psychedelic research. As the field moves toward pivotal Phase 3 trials and potential regulatory submissions in the late 2020s, the integration of social cognition endpoints could reshape both the scientific narrative and the regulatory pathway for psilocybin and related compounds. For now, sponsors, investigators, and policymakers should engage in open dialogue to align on meaningful, patient-centered outcomes that reflect the full spectrum of therapeutic change.

How we research: This article was written and reviewed by Dr. Alex Morgan, PhD (Neuroscience), Psychedelic Research Journal contributing editor, on 2026-10-07. All claims are supported by direct links to primary regulatory and clinical trial sources.